Explore
Validate
Learn
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF2150 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal Complement Component C5a Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects mouse Complement Component C5a in direct ELISAs and Western blots. In direct ELISAs and Western blots (non-reducing conditions), approximately 50% cross-reactivity with recombinant human Complement Component C5a is observed.
- Reactivity
- Mouse
- Host
- Goat
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation.
Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.
Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.
Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009 Aug;9(8):1784-95
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009 Aug;9(8):1784-95
Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.
Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS
Journal of immunology (Baltimore, Md. : 1950) 2007 Nov 1;179(9):5793-802
Journal of immunology (Baltimore, Md. : 1950) 2007 Nov 1;179(9):5793-802
Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.
Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS
Journal of immunology (Baltimore, Md. : 1950) 2007 Nov 1;179(9):5793-802
Journal of immunology (Baltimore, Md. : 1950) 2007 Nov 1;179(9):5793-802
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Chemotaxis Induced by Complement Component C5a and Neutralization by Mouse Complement Component C5a Antibody. Recombinant Mouse Complement Component C5a (Catalog # 2150-C5) chemoattracts the J774A.1 mouse reticulum cell sarcoma macrophage cell line in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Complement Component C5a (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Complement Component C5a Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2150). The ND50 is typically 0.6-3.0 µg/mL.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- N-Acetyl-beta -D-Glucosaminidase Release Induced by Complement Component C5a and Neutralization by Mouse Complement Component C5a Antibody. N-Acetyl-beta -D-Glucosaminidase Release Induced by Complement Component C5a and Neutralization by Mouse Complement Component C5a Antibody.
